AnHorn Medicines
Taipei, Taiwan· Est.
AI‑driven protein degradation company developing BIGPRO® therapeutics for cancer, neurodegeneration and aging.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven protein degradation company developing BIGPRO® therapeutics for cancer, neurodegeneration and aging.
OncologyNeurodegenerationAging
Technology Platform
BIGPRO® protein degrader technology combined with AIMCADD® AI‑driven drug design platform for rapid identification of high‑affinity target and E3 ligase binders.
Opportunities
AI‑enabled TPD can rapidly expand the druggable proteome, offering first‑in‑class therapies for high‑unmet‑need diseases and attracting partnership interest from large pharma.
Risk Factors
Clinical efficacy of novel degraders remains unproven; regulatory pathways for AI‑designed molecules are still evolving, and substantial capital is required to advance multiple candidates.
Competitive Landscape
Competes with other TPD innovators such as Arvinas, C4 Therapeutics, and Kymera, but differentiates through its AI‑centric discovery engine and proprietary BIGPRO® chemistry.